Market news

Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above

Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been init

Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical

Topline data expected to be available late 3Q2027SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for th

Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and China Breakthrough Therapy designation.

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech Co., Lt